QNRX (STOCKS)
Quoin Pharmaceuticals, Ltd. American Depositary Shares
$8.270000
+0.250000 (+3.12%)
Prev close: $8.020000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Myers
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4.86M
- Employees
- 3
- P/E (TTM)
- -0.02
- P/B (TTM)
- -4.00
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-6.71 | $-5.08 | -1.6338 | -32.19% |
|
Jun 2025 (Q2)
|
$-6.28 | $-7.56 | +1.2782 | +16.91% |
|
Mar 2025 (Q1)
|
$-6.50 | $-6.19 | -0.3121 | -5.04% |
|
Dec 2024 (Q4)
|
$-12.25 | $-16.42 | +4.1720 | +25.40% |
Financial Statements
| Nonoperating Income/Loss | $407.79K |
| Selling, General, and Administrative Expenses | $6.42M |
| Research and Development | $7.76M |
| Income/Loss From Continuing Operations After Tax | -$13.77M |
| Income/Loss From Continuing Operations Before Tax | -$13.77M |
| Net Income/Loss | -$13.77M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.77M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $6.42M |
| Current Assets | $6.02M |
| Prepaid Expenses | $602.65K |
| Other Current Assets | $5.41M |
| Noncurrent Assets | $408.33K |
| Intangible Assets | $408.33K |
| Liabilities | $7.64M |
| Current Liabilities | $5.76M |
| Accounts Payable | $1.86M |
| Other Current Liabilities | $3.90M |
| Noncurrent Liabilities | $1.87M |
| Equity | -$1.21M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$1.21M |
| Liabilities And Equity | $6.42M |
| Net Cash Flow From Operating Activities | -$10.74M |
| Net Cash Flow From Operating Activities, Continuing | -$10.74M |
| Net Cash Flow From Investing Activities | $3.81M |
| Net Cash Flow From Investing Activities, Continuing | $3.81M |
| Net Cash Flow From Financing Activities | $5.64M |
| Net Cash Flow From Financing Activities, Continuing | $5.64M |
| Net Cash Flow | -$1.29M |
| Net Cash Flow, Continuing | -$1.29M |
| Comprehensive Income/Loss | -$13.77M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.77M |
| Other Comprehensive Income/Loss | $0.00 |